Clinical Trials Logo

Clinical Trial Summary

The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in prefrontal cortex as measured by pharmacoBOLD fMRI (also termed resting BOLD fMRI).


Clinical Trial Description

This study evaluates the effects of POMA at selected doses on ketamine-stimulated glutamate increase in the prefrontal cortex hypothesized to simulate the synaptic dysregulation that occurs endogenously in the pathogenesis of schizophrenia. The purpose of this is: 1) to determine whether the low dose (40 mg BID) utilized in recent (failed) clinical trials is sufficient to engage the primary target and 2) whether a higher (160 mg BID) dose, representing the maximum tolerated dose of POMA, engages the target to a greater degree. This study will further validate pharmacoBOLD as biomarker of mGluR2/3 target engagement, permitting its future use in other glutamatergic drug development. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02919774
Study type Interventional
Source New York State Psychiatric Institute
Contact
Status Completed
Phase Phase 1
Start date October 2016
Completion date May 25, 2018

See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Recruiting NCT02572700 - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Recruiting NCT01888783 - Two Measures of Tactile Acuity in CRPS Type I Patients N/A
Recruiting NCT03741478 - Intranasal Insulin and Olanzapine Study in Healthy Volunteers Phase 1
Completed NCT01460394 - Normative Data of Brain Network Activation in Adolescents and Young Adults
Completed NCT00771940 - Peripheral Metabolic Effects of Ghrelin Phase 1
Recruiting NCT06068322 - Supramaximal High-Intensity Interval Training in People With and Without Chronic Obstructive Pulmonary Disease N/A
Active, not recruiting NCT02652195 - Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II Phase 2
Recruiting NCT06270108 - The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia Early Phase 1
Withdrawn NCT04320966 - Neurovascular Complications and White Matter Damage in Acquired Anemias
Recruiting NCT05046184 - Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets Phase 2
Completed NCT03134963 - Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
Completed NCT03081546 - Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease
Completed NCT04085094 - Gender Differences in Renal Functioning and Disease
Completed NCT03520543 - [11C]Yohimbine PET Study of alpha2-AR Phase 1
Recruiting NCT06098612 - PET Imaging Evaluation of [11C]SY08 Early Phase 1
Completed NCT02134951 - Biomarker Assessment of Glutamatergic Target Engagement Phase 4
Active, not recruiting NCT05056610 - Confocal Laser Endomicroscopy to Determine Influence of Food Antigens on Mucosal Integrity N/A
Recruiting NCT05656378 - A Repository to Study Host-Microbiome Interactions in Health and Disease
Recruiting NCT05869968 - SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI